Immuron Business Update - Ateria Health launches Juvia™ in Australia
2023年7月11日 - 7:00PM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and
globally integrated biopharmaceutical company that has developed
two commercially available oral immunotherapeutic products for the
treatment of gut mediated diseases, is pleased to announce that
Ateria Health Australia Pty Ltd, a subsidiary of Ateria Health
Limited (“Ateria”), has launched Juvia™ in Australia.
Immuron completed settlement of a strategic
investment in Ateria on 16 November 2022 (17.5% shareholding).
Ateria is a UK based biotech company that develops and distributes
supplements for overall health, including products that strengthen
the gut microbiome.
In response to shareholder requests for an
update on Ateria activities, the Company is sharing the pertinent
parts of an update recently provided to Ateria shareholders by
Ateria’s CEO, Neil Wickers:
“Our first brand Juvia™ launched in the UK last
year targeting people who suffer from irritable bowel syndrome
(IBS). It contains our breakthrough patent pending natural
ingredient ERME™. We are selling direct to consumer via our website
www.juvia.me. The consumer response has been phenomenal, and we
have received 100’s of life changing testimonials. On our page of
the independent review site Trustpilot, we are rated “excellent”
and the leading UK lifestyle magazine has awarded us their reader
recommended accreditation. We are seeing sales in the UK grow
month-on-month and we are pleased with the momentum. We continually
refine our digital marketing strategy, and we now have a much
deeper understanding of how to identify, attract and convert target
customers.
Juvia™ Australia
We are excited to announce we are launching in
Australia this week. Our Australian website www.juvia.me is now
live and we are fulfilling orders with free standard shipping from
our logistics partner in Melbourne. Given that we have a loyal
following in Australia with many ordering via our UK site we expect
sales to inform our Australian launch. We will be supporting launch
with Google advertising, social media advertising on Facebook,
Instagram and TikTok and PR in local and national media.
New Clinical Study Underway
We now have 14 studies on ERME™ in humans,
horses, dogs and birds all showing consistent results. We have
shown that ERME™ improves the diversity of the microbiome
(improving its capability and resilience), increases good bacteria
(particularly those that produce butyrate, which is important for
the cells of the gut wall, as well as those that have an
anti-inflammatory response), reduces toxins and improves symptoms
of IBS.
Our latest study is with the NHS in Swansea,
Wales, and will look at people diagnosed with IBS due to
malfermentation of carbohydrates in the gut. The first patients
have been recruited and results should be available later this
year.
We are also in the planning stages for an
observational study in Melbourne later this year with Dr Harry
Frydenberg, one of Australia’s leading gastric surgeons, as
Principal Investigator.”
Immuron continues to develop plans for launch of
Travelan® in UK / Europe including regulatory pathways, options for
label claims, import requirements, distribution requirements and
supply chain planning. Ateria is launching Juvia™ in Australia
direct to consumer under the Australia New Zealand Food Standards
Code. Immuron is assisting Ateria with evaluating the requirements
for including Juvia™ in the Australian Register of Therapeutic
Goods as a complementary medicine. This is a precursor for launch
of Juvia™ in the pharmacy sales channel.
This release has been authorised by the
directors of Immuron Limited.
Contact Information:Steven
LydeamoreChief Executive OfficerPh: +61 (0)3 9824
5254info@immuron.comhttps://www.immuron.com.au/form/contact-us/
About ImmuronImmuron Limited
(ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical
company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of inflammatory
mediated and infectious diseases.
For more information visit:
http://www.immuron.com
Immuron (NASDAQ:IMRN)
過去 株価チャート
から 8 2024 まで 9 2024
Immuron (NASDAQ:IMRN)
過去 株価チャート
から 9 2023 まで 9 2024